Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer healt... [ Read More ]
The intrinsic value of one CTLT stock under the Base Case scenario is 57.41 USD. Compared to the current market price of 37.18 USD, Catalent Inc is Undervalued by 35%.
Intrinsic Value History...
Our system is conducting in-depth analyses to map out the stock's valuation journey. Thank you for waiting.
Last Video News
Last Important Events
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. The company is headquartered in Somerset, New Jersey and currently employs 17,300 full-time employees. The company went IPO on 2014-07-31. Its segments include Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment is engaged in providing formulation, development, and manufacturing services for soft capsules, as well as largescale manufacturing of oral solid dose forms. The Biologics segment provides biologic cell-line, cell therapy and viral vector gene therapy development and manufacturing services. The Oral and Specialty Delivery segment provides formulation development and manufacturing across a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is engaged in manufacturing, packaging, distribution and inventory management for drugs and biologics in clinical trials.